Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Companyâ€™s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkinâ€™s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	4M 3.45M 3.18M 2.98M 5.6M 378M 5.65M 37.54M 14.67M 185M 15.02M 14.71M 641M	P/E Ratio 2024	-0.19x	P/E Ratio 2025	-0.15x
Enterprise Value	30.28M 26.1M 24.02M 22.53M 42.33M 2.86B 42.75M 284M 111M 1.4B 114M 111M 4.85B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	72.64%	Yield 2024 *	-	Yield 2025	-

04:52pm	Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML	CI
04:45pm	Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026	MT
05-29	Aptose Biosciences Says Acquisition by Hanmi Delayed Until June	MT
05-29	Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed	RE
05-14	Aptose Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-01	Aptose Shareholders Approve Acquisition By Hanmi Pharmaceutical in "Go Private" Transaction	MT
04-01	Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Aptose Biosciences Inc. - Shareholder/Analyst Call
03-31	Aptose Biosciences Inc. Auditor Raises 'Going Concern' Doubt	CI
03-23	Leading independent proxy advisory firm Glass Lewis endorses Aptose plan of arrangement	RE
03-23	Aptose Biosciences Brief: Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement With Hanmi Pharmaceutical	MT
03-19	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical	RE
03-19	Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical	MT

03-19	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical	RE
03-19	Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical	MT
11/06/24	HC Wainwright Adjusts Price Target on Aptose Biosciences to $7 From $23, Maintains Buy Rating	MT
10/11/23	RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk	MT
11/08/23	Oppenheimer Adjusts Aptose Biosciences Price Target to $15 From $50, Maintains Outperform Rating	MT

03:37pm	Aptose Biosciences : Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	PU
03:30pm	Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	AQ
05-29	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
05-14	Aptose Biosciences: Q1 Earnings Snapshot	AQ
05-14	Aptose Biosciences : Reports First Quarter 2026 Results	PU

12-05	Tokenización: ¿Va a cambiar tanto la vida de los inversores?
12-05	Universo cripto: la tokenizzazione cambierà davvero la vita degli investitori?
09/09/23	Vastzetting: Ethereum scheert hoge toppen - cryptonieuws
08/09/23	Staking: Ethereum raggiunge nuove vette - Resoconto Cripto

Aptose Biosciences Stock Nasdaq

Stocks

Pharmaceuticals

Valuation: Aptose Biosciences

Latest news : Aptose Biosciences

Last Transcript: Aptose Biosciences

Analysts' recommendations: Aptose Biosciences

Press Releases: Aptose Biosciences

News in other languages: Aptose Biosciences

Quotes and Performance

Managers and Directors: Aptose Biosciences

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
William Rice CEO	Chief Executive Officer	67	28/10/2013
C. Payne DFI	Director of Finance/CFO	63	27/06/2022
Victor Montalvo-Lugo CTO	Chief Tech/Sci/R&D Officer	-	01/11/2019

Director	Title	Age	Since
Denis Burger BRD	Director/Board Member	82	19/09/2007
Mark Vincent BRD	Director/Board Member	73	19/09/2007
Warren Whitehead BRD	Director/Board Member	73	07/04/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOSE BIOSCIENCES	-7.92%	+21.79%	-	-	4M
ELI LILLY AND COMPANY	-0.13%	-1.78%	+39.76%	+148.64%	1,010B
JOHNSON & JOHNSON	-1.75%	+1.33%	+51.55%	+43.68%	580B
ABBVIE INC.	-2.67%	-0.43%	+16.38%	+63.46%	402B
ROCHE HOLDING AG	-0.46%	0.00%	+21.28%	+19.14%	330B
NOVARTIS AG	-1.52%	+1.90%	+23.73%	+34.08%	281B
ASTRAZENECA PLC	-1.95%	-4.32%	+22.02%	+12.96%	280B
NOVO NORDISK A/S	-0.57%	+5.00%	-42.66%	-48.28%	197B
AMGEN INC.	-2.80%	+1.96%	+19.27%	+54.31%	192B
GILEAD SCIENCES, INC.	-3.88%	-3.06%	+12.04%	+57.18%	156B
Average	-1.97%	+0.84%	+18.15%	+42.80%	380.97B
Weighted average by Cap.	-1.15%	+1.04%	+27.32%	+67.19%

	2024	2025
Net sales	-	-
Net income	-25.43M -21.92M -20.17M -18.92M -35.55M -2.4B -35.9M -238M -93.15M -1.18B -95.43M -93.41M -4.07B	-25.47M -21.95M -20.2M -18.95M -35.6M -2.41B -35.96M -239M -93.29M -1.18B -95.57M -93.55M -4.08B
Net Debt	4.49M 3.87M 3.56M 3.34M 6.27M 424M 6.33M 42.08M 16.44M 208M 16.84M 16.48M 719M	26.28M 22.65M 20.84M 19.55M 36.73M 2.48B 37.1M 246M 96.25M 1.22B 98.61M 96.52M 4.21B